AstraZeneca announced that its asthma inhaler, Breztri Aerosphere, has met all primary goals in two late-stage clinical trials involving patients with uncontrolled asthma.
The trials demonstrated clinically meaningful improvements in lung function, showing that Breztri may offer a more effective treatment option for those struggling to manage their symptoms.
Breztri is a triple-combination therapy that includes budesonide, glycopyrrolate, and formoterol. The study outperformed dual maintenance therapies by substantially benefiting patients’ respiratory function.
Asthma is a chronic inflammatory disease of the airways marked by muscle tightening and inflammation, making breathing difficult.
According to the World Health Organization (WHO), asthma affected 262 million people worldwide in 2019 and caused 455,000 deaths.
Breztri Aerosphere has already been approved for the treatment of chronic obstructive pulmonary disease (COPD), and the new findings further support its potential for treating asthma.
